Healthcare spending in the case of a HPV16/18 population-wide vaccination programme

Scandinavian Journal of Public Health

Volumn 40, Issue 5, 2012, Pages 406-411

  Vanagas, Giedrius ^a   Padaiga, Zilvinas ^a  

^a LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

Author keywords

Cervical cancer; economic effectiveness; healthcare spending; Lithuania; vaccination

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CHILD; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LITHUANIA; PAPILLOMAVIRUS INFECTION; PREVENTIVE HEALTH SERVICE; STATISTICS; UTERINE CERVIX TUMOR;

CHILD; COST-BENEFIT ANALYSIS; FEMALE; HEALTH EXPENDITURES; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNIZATION PROGRAMS; LITHUANIA; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PROGRAM EVALUATION; UTERINE CERVICAL NEOPLASMS;

EID: 84865208854     PISSN: 14034948     EISSN: 16511905     Source Type: Journal    
DOI: 10.1177/1403494812455467     Document Type: Article

References (27)

1. Parkin D.M. Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24 Suppl 3:S11–S25.
2. Arbyn M. Antoine J. Magi M. Smailyte G. Stengrevics A. Suteu O. et al. Trends in cervical cancer incidence and mortality in the Baltic countries, Bulgaria and Romania. Int J Cancer 2011;128(8):1899–907.
3. Jariene K. Vaitkiene D. Bartusevicius A. Tvarijonaviciene E. Minkauskiene M. Nadisauskiene R. et al. Prevalence of human papillomavirus types 16, 18, and 45 in women with cervical intraepithelial changes: associations with colposcopic and histological findings. Medicina (Kaunas ) 2012;48(1):22–30.
4. Arbyn M. Raifu A.O. Autier P. Ferlay J. Burden of cervical cancer in Europe: estimates for 2004. Ann Oncol 2007;18(10):1708–15.
5. Arbyn M. Antoine J. Valerianova Z. Magi M. Stengrevics A. Smailyte G. et al. Trends in cervical cancer incidence and mortality in Bulgaria, Estonia, Latvia, Lithuania and Romania. Tumori 2010;96(4):517–23.
6. Goldie S.J. O'Shea M. Kim J.J. Finding consensus on cervical cancer prevention. Am J Public Health 2012;102(6):1050–1051.
7. Mao C. Koutsky L.A. Ault K.A. Wheeler C.M. Brown D.R. Wiley D.J. et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006; 107(1):18–27.
8. Ault K.A. Long-term efficacy of human papillomavirus vaccination. Gynecol Oncol 2007;107(2 Suppl):S27–S30.
9. Termrungruanglert W. Havanond P. Khemapech N. Lertmaharit S. Pongpanich S. Khorprasert C. et al. Cost and effectiveness evaluation of prophylactic HPV vaccine in developing countries. Value Health 2012;15(1 Suppl):S29–S34.
10. Dasbach E.J. Elbasha E.H. Insinga R.P. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 2006;28:88–100.
11. Elbasha E.H. Dasbach E.J. Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007;13(1):28–41.
12. Coupe V.M. van Ginkel J. de Melker H.E. Snijders P.J. Meijer C.J. Berkhof J. HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness. Int J Cancer 2009;124(4):970–8.
13. Goldie S.J. O'Shea M. Diaz M. Kim S.Y. Benefits, cost requirements and cost-effectiveness of the HPV 16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Reprod Health Matters 2008;16(32):86–96.
14. Vanagas G. Padaiga Z. Kurtinaitis J. Logminiene Z. Cost-effectiveness of 12- and 15-year-old girls’ human papillomavirus 16 / 18 population-based vaccination programmes in Lithuania. Scand J Public Health 2010;38(6):639–47.
15. Clifford G. Franceschi S. Diaz M. Munoz N. Villa L.L. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24 Suppl 3:S26–S34.
16. Saranath D. Khan Z. Tandle A.T. Dedhia P. Sharma B. Contractor R. et al. HPV16/18 prevalence in cervical lesions / cancers and p 53 genotypes in cervical cancer patients from India. Gynecol Oncol 2002;86(2):157–62.
17. Hughes J.P. Garnett G.P. Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002;13(6):631–9.
18. Stanley M. Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer. Br J Cancer 2007;96(9):1320–3.
19. Harper D.M. Franco E.L. Wheeler C.M. Moscicki A.B. Romanowski B. Roteli-Martins C.M. et al. Sustained efficacy up to 4.5 years of a bivalent L 1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367(9518):1247–55.
20. Paavonen J. Jenkins D. Bosch F.X. Naud P. Salmeron J. Wheeler C.M. et al. Efficacy of a prophylactic adjuvanted bivalent L 1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369(9580):2161–70.
21. HPV vaccination recommended for 9- to 26-year-old male patients. AIDS Patient Care STDS 2010;24(8):531.
22. Committee opinion no. 467: human papillomavirus vaccination. Obstet Gynecol 2010;116(3):800–3.
23. Insinga R.P. Dasbach E.J. Elbasha E.H. Liaw K.L. Barr E. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives. Cancer Epidemiol Biomarkers Prev 2007;16(4):709–15.
24. Holmes J. Hemmett L. Garfield S. The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies. Eur J Health Econ 2005;6(1):30–37.
25. Lewsey J.D. Leyland A.H. Murray G.D. Boddy F.A. Using routine data to complement and enhance the results of randomised controlled trials. Health Technol Assess 2000;4(22):1–55.
26. Birnbaum H.G. Cremieux P.Y. Greenberg P.E. Le Lorier J. Ostrander J.A. Venditti L. Using healthcare claims data for outcomes research and pharmacoeconomic analyses. Pharmaco Economics 1999;16(1):1–8.
27. Von Euler-Chelpin M. Lynge E. Rebolj M. Register-based studies of cancer screening effects. Scand J Public Health 2011;39(7 Suppl):158–64.